Nucleus RadioPharma
Website to be confirmed.
About Nucleus RadioPharma
A CDMO / CMO player with a presence on the SNMMI floor; commercial activity worth a closer look.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- PR Newswire · 2026-10-19Nucleus Radiopharma announces Phase II readout for lead theranostic candidateDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
- Nuclear Medicine Today · 2026-05-12Nucleus Radiopharma expands cyclotron capacity to meet Lu-177 demandCoverage notes the company's growing footprint in the radioligand therapy space.
- STAT News · 2026-04-05Nucleus Radiopharma signs supply agreement to support late-stage trialsThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- Imaging Wire · 2026-07-26Nucleus Radiopharma appoints new Chief Medical Officer ahead of pivotal trialIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
- BioPharma Reporter · 2026-06-03Nucleus Radiopharma publishes dosimetry data at SNMMI 2026The announcement comes amid tightening Mo-99 and Lu-177 supply.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →CDL Nuclear Technologies
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on CDL Nuclear Technologies.
View profile →Jubilant Radiopharma
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Jubilant Radiopharma.
View profile →